ABC | Volume 111, Nº2, August 2018

Original Article Farsky et al Persistent inflammation after stent Arq Bras Cardiol. 2018; 111(2):134-141 This is an open-access article distributed under the terms of the Creative Commons Attribution License 6. Thielmann M, Neuhauser M, Knipp S, Kottenberg-Assenmacher E, Marr A, Pizanis N, et al. Prognostic impact of previous percutaneous coronary intervention in patients with diabetes mellitus and triple-vessel disease undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg. 2007;134(2):470-6. 7. Ueki C, Sakaguchi G, Akimoto T, Shintani T, Ohashi Y, Sato H. Influence of previous percutaneous coronary intervention on clinical outcome of coronary artery bypass grafting: a meta-analysis of comparative studies. Interact Cardiovasc Thorac Surg. 2015;20(4):531-7. 8. Yap CH, Yan BP, Akowuah E, Dinh DT, Smith JA, Shardey GC, et al. Does prior percutaneouscoronaryinterventionadverselyaffectearlyandmid-termsurvival after coronary artery surgery? JACCCardiovasc Interv. 2009;2(8):758-64. 9. Borges JC, Lopes N, Soares PR, Góis AF, Stolf NA, Oliveira SA, et al. Five-year follow-up of angiographic disease progression after medicine, angioplasty, or surgery. J Cardiothorac Surg. 2010 Oct 26;5:91. 10. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002 June 18;3(7):RESEARCH0034. 11. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-8. 12. Wu M, Gu X, Li X, Li Y, Zhou H, Lu G, et al. C-reactive protein and inflammatory cytokines during percutaneous coronary intervention. J Vasc Res. 2016;53(1-2):39-48. 13. Yoneda S, Abe S, Kanaya T, Oda K, Nishino S, KageyamaM, et al. Late-phase inflammatory response as a feature of in-stent restenosis after drug-eluting stent implantation. Coron Artery Dis. 2013;24(5):368-73. 14. KimWJ, Kang YJ, Suk K, Park JE, Kwon BS, LeeWH. Comparative analysis of the expression patterns of various TNFSF/TNFRSF in atherosclerotic plaques. Immunol Invest. 2008;37(4):359-73. 15. DepreC,RibichiniF,WijnsW.Morphologicalanalysisofatheroscleroticplaque retrievedbycoronaryatherectomy.Semin IntervCardiol.2000;5(4):175-84. 16. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol. 2003;3(9):745-56. 17. Gerdes N, Seijkens T, Lievens D, Kuijpers MJ, Winkels H, Projahn D, et al. Platelet CD40 exacerbates atherosclerosis by transcellular activation of endothelial cells and leukocytes. Arterioscler Thromb Vasc Biol. 2016;36(3):482-90. 18. Wang P, Mariman E, Renes J, Keijer J. The secretory function of adipocytes in the physiology of white adipose tissue. J Cell Physiol. 2008;216(1):3-13. 19. Kuryszko J, Slawuta P, Sapikowski G. Secretory function of adipose tissue. Pol J Vet Sci. 2016;19(2):441-6. 20. Lee WH, Kim SH, Lee Y, Lee BB, Kwon B, Song H, et al. Tumor necrosis factor receptor superfamily 14 is involved in atherogenesis by inducing proinflammatory cytokines and matrix metalloproteinases. Arterioscler Thromb Vasc Biol. 2001;21(12):2004-10. 21. SchuettH,LuchtefeldM,GrothusenC,GroteK,SchiefferB.Howmuch istoo much? Interleukin-6 and its signalling in atherosclerosis. Thromb Haemost. 2009;102(2):215-22. 22. Hartman J, FrishmanWH. Inflammation and atherosclerosis: a reviewof the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy. Cardiol Rev. 2014;22(3):147-51. 23. Kazmierczak E, Grajek S, Kowal J, Chmara E, Grygier M, Pyda M, et al. Prognostic usefulness of IL-6 and VEGF for the occurrence of changes in coronary arteries of patients with stable angina and implanted stents. Eur Rev Med Pharmacol Sci. 2014;18(15):2169-75. 24. Szkodzinski J, Blazelonis A, Wilczek K, Hudzik B, Romanowski W, Gasior M, et al. The role of interleukin-6 and transforming growth factor-beta1 in predictingrestenosiswithinstented infarct-relatedartery. Int J Immunopathol Pharmacol. 2009;22(2):493-500. 141